Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological DiseasesBusiness Wire • 10/24/24
Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024Zacks Investment Research • 10/23/24
Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales ExpectationsInvestors Business Daily • 10/23/24
[Ad hoc announcement pursuant to Art. 53 LR] Roche's strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine monthsGlobeNewsWire • 10/23/24
Roche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind studyGlobeNewsWire • 10/18/24
Genentech's Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind StudyBusiness Wire • 10/18/24
Roche receives FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOYPRNewsWire • 10/18/24
Majority of children with spinal muscular atrophy (SMA) treated with Roche's Evrysdi are able to sit, stand and walk independently, two-year data demonstrateGlobeNewsWire • 10/14/24
Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech's Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data DemonstrateBusiness Wire • 10/14/24
FDA approves Roche's Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutationGlobeNewsWire • 10/11/24
FDA Approves Genentech's Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA MutationBusiness Wire • 10/10/24
Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOYGlobeNewsWire • 10/10/24
Survey commissioned by Roche shows that HPV infection, which causes 99% of all cervical cancer cases, remains largely misunderstood by the general publicPRNewsWire • 10/08/24
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK InhibitorsZacks Investment Research • 10/01/24
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary GoalsZacks Investment Research • 09/26/24
Positive phase III results for Roche's Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritisGlobeNewsWire • 09/26/24